Cite
HARVARD Citation
O'Malley, D. et al. (n.d.). O011/#496 Mirvetuximab soravtansine and bevacizumab in folate receptor αlpha-positive ovarian cancer: efficacy in patients with and without prior bevacizumab. International journal of gynecological cancer. pp. A7-A8. [Online].